

Pain Management: Part 1: Managing Acute and Postoperative Dental Pain

Daniel E. Becker, DDS

Associate Director of Education, General Dental Practice Residency, Miami Valley Hospital, Dayton, Ohio

Safe and effective management of acute dental pain can be accomplished with nonopioid and opioid analgesics. To formulate regimens properly, it is essential to appreciate basic pharmacological principles and appropriate dosage strategies for each of the available analgesic classes. This article will review the basic pharmacology of analgesic drug classes, including their relative efficacy for dental pain, and will suggest appropriate regimens based on pain intensity. Management of chronic pain will be addressed in the second part of this series.

Key Words: Pain management; Analgesics; Postoperative pain; Dental pain.

Pain is a complex experience consisting of a specific sensation and the reactions evoked by that sensation. Conventional analgesics either interrupt ascending nociceptive impulses or depress their interpretation within the central nervous system (CNS). A variety of so-called “analgesic adjuncts” have proven efficacy for managing chronic pain but will not be addressed in this article. They include various antidepressants and anticonvulsants that either enhance descending inhibitory pathways or modulate excitatory neural traffic that amplifies pain interpretation. These agents have marginal benefit in the management of acute pain, and they are not regarded as “analgesics” in the conventional sense. Management of chronic pain will be the topic of a subsequent continuing education article in this journal.

Analgesics are classified as opioids and nonopioids, but dated terms like *narcotic* and *non-narcotic* are used interchangeably. Formerly, it was believed that opioids acted only within the brain and spinal cord, but the action of nonopioids was confined to the periphery (ie, the site of injury). This explanation is no longer tenable, however; both are known to act centrally and peripherally.^{1,2} In fact, the feature that best distinguishes these analgesic classes is their mechanism of action. Opioids activate specific receptors in a manner identical to opiates, such as morphine. Nonopioids interrupt prostaglandin synthesis, thereby resembling aspirin in action.

NONOPIOID ANALGESICS

The nonopioid analgesics include acetaminophen (APAP) and the nonsteroidal anti-inflammatory drugs (NSAIDs). The analgesic efficacy of these agents is typically underestimated. This is unfortunate because they generally are equivalent or superior to opioids for managing musculoskeletal pain, and they produce a lower incidence of side effects, including the potential for abuse. Dental pain is included in the musculoskeletal category, and for decades studies have repeatedly found that NSAIDs are generally superior to opioids at conventional dosages.³⁻⁵ This principle will be revisited during the final portion of this article, but at this time it is important to review essential pharmacological features of the nonopioids.

NSAIDS

Actions and Effects. Ibuprofen is conventionally regarded as the prototype of this large group of synthetic compounds known for their analgesic, antipyretic, and anti-inflammatory efficacy. These therapeutic effects and their most notable side effects can be explained almost entirely by their ability to inhibit the cyclooxygenase (COX) required for synthesis of various families of prostanoids.⁶ This action is illustrated and further explained in Figure 1.

Precautions and Side Effects. Clinical use of NSAIDs is predicated on their ability to reduce the

Address correspondence to Dr Becker at debecker@mvh.org.




Figure 1. Synthesis and function of prostanoids. Perturbation of cell membranes can be mediated by diverse endogenous and exogenous stimuli. This triggers activity of phospholipase A₂, releasing arachidonic acid from the phospholipids making up the membrane. Two families of cyclooxygenases (COX-1 and COX-2) convert this fatty acid to a variety of so-called prostanoids that are unique to the particular cell or tissue and include prostaglandins, thromboxanes, and prostacyclin. Each of these prostanoids has specific physiological functions, some of which are listed in the table within this figure. Most nonsteroidal anti-inflammatory drugs (NSAIDs) are nonselective and inhibit both COX-1 and COX-2 families. Celecoxib (Celebrex) is representative of agents that selectively inhibit COX-2; it reduces pain and inflammation with little or no influence on gastric mucosa. However, this selective inhibition may promote greater synthesis of prostanoids derived from COX-1, including thromboxane-mediated effects leading to possible thrombotic events (eg, myocardial infarction, stroke). Arachidonic acid is also a substrate for lipoxygenase that catalyzes the formation of leukotrienes known for their anaphylactoid effects, including bronchospasm and upper airway edema. As NSAIDs inhibit the activity of cyclooxygenases, a greater portion of arachidonic acid can be converted to leukotrienes by lipoxygenase. This may not be tolerated by patients with atopy because they experience pseudoallergic syndromes.

synthesis of prostaglandins implicated in pain, fever, and inflammation. However, these agents are hardly selective in this goal and also inhibit the production of additional prostanoids that perform useful physiological functions. This accounts for potential side effects and contraindications.

The most frequent side effects of NSAIDs are related to their gastrointestinal (GI) toxicity. Prostaglandins stimulate the production of a mucous lining that protects the stomach and small intestine. The erosive and ulcerative side effects common to NSAIDs are attributed to their inhibiting the synthesis of these particular prostaglandins. This action not only occurs locally as orally administered drug lies in contact with gastric mucosa but also follows absorption and systemic distribution to the GI mucosa. Parenteral administration does not preclude a risk for GI erosions and ulcerations. It is important to distinguish dyspepsia (upset

stomach) from GI toxicity, which reflects actual mucosal damage. The incidence of dyspepsia attributed to NSAIDs does not correlate with mucosal injury. Although less likely to produce gastric upset, buffered aspirin carries similar risk for mucosal damage as regular aspirin.⁷

The ability of NSAIDs to inhibit cyclooxygenases in platelets reduces the synthesis of thromboxane A₂, which normally contributes to platelet aggregation. This accounts for the so-called antiplatelet effect of these agents and is a consideration following surgical procedures. However, aspirin is the only NSAID that has proven effective in preventing thrombotic events such as acute coronary syndromes or stroke. This is so because the antiplatelet action of aspirin is irreversible, lasting the life span of the platelet (10–14 days). Other NSAIDs bind weakly and reversibly to platelet cyclooxygenases, which results in loss of their mild antiplatelet influence after drug elimination.⁸ Although nonaspirin NSAIDs all prolong bleeding times to some degree, this does not correlate with significant clinical bleeding following minor surgical procedures. However, nonaspirin NSAIDs generally are withheld before major thoracic, abdominal, or orthopedic procedures. If aspirin is medically necessary for patients, such as those with endovascular stents who are at risk for life-threatening clot formation, it should not be withdrawn.

NSAIDs should be avoided in patients who suffer bleeding disorders and in those taking anticoagulants such as warfarin and powerful antiplatelet drugs such as clopidogrel (Plavix). Patients receiving monotherapy with low-dose aspirin are not as great a concern but should be considered. The issue with NSAIDs is due not so much to their antiplatelet action but to NSAID-induced injury of GI mucosa that may bleed far more profusely in this patient population. Aspirin provides a maximum antiplatelet influence at a very low dose—80 mg daily—and frequently is prescribed in combination with warfarin without consequence because such doses have a lower potential to produce gastric insult. In contrast, other NSAIDs increase the risk for GI bleeding twofold to threefold in patients medicated with clopidogrel (Plavix) and fourfold to fivefold in those taking warfarin.⁹ All concerns related to NSAID-induced mucosal injury are particularly important for older patients, especially those taking anti-thrombotic medications, including low-dose aspirin.

Prostaglandins play an essential role in renal perfusion, and diminished levels of these are believed to account for reported cases of nephrotoxicity after long-term NSAID use. In the healthy patient, nephrotoxicity attributed to NSAIDs requires high doses for extended periods (eg, a year or longer).¹⁰ However, a patient with compromised renal function relies more heavily

on prostaglandins for adequate function, and acute renal failure can occur within 24 hours of NSAID administration. NSAIDs must never be prescribed for patients who have known or questionable renal function. The ability of NSAIDs to alter renal function has resulted in concern regarding their long-term use in patients with hypertension and heart failure.^{11,12} Altered renal function accompanies the pathogenesis of these disorders, and any further renal decline may exacerbate their condition. This concern has not been found relevant with short-term NSAID use (eg, 5–7 days).

By inhibiting cyclooxygenase, NSAIDs shunt the arachidonic pathway toward leukotriene synthesis (Figure 1). Leukotrienes mediate a variety of tissue responses, including those associated with bronchospasm and anaphylaxis.¹³ Certain individuals may be extremely sensitive to even subtle elevation in leukotriene synthesis, which may result in signs and symptoms of allergic response. It is recommended that the term *aspirin or NSAID intolerance* should be used to distinguish this reaction from true hypersensitivity responses mediated by immunoglobulin (Ig)E. Acetaminophen is the conventional alternative for patients reporting an allergic reaction to any NSAID, unless the patient can identify a particular product that he or she has tolerated without problem in the past.

In summary, NSAIDs are contraindicated for patients who have a current history of nephropathy, erosive or ulcerative conditions of the GI mucosa, anticoagulant therapy, hemorrhagic disorders, or intolerance or allergy to any NSAID. They also should be avoided during pregnancy because prostaglandins maintain patency of the ductus arteriosus during fetal development. Although this concern is most relevant during the third trimester, NSAIDs generally should be avoided throughout pregnancy. In all cases where NSAIDs are contraindicated, acetaminophen is the conventional nonopioid alternative.

Drug Interactions. After prolonged use, NSAIDs may interfere with the effectiveness of most classes of antihypertensive medications; calcium channel blockers are a notable exception. The precise mechanism for this interaction is unknown but is believed to be related to diminished vasodilator actions attributed to renal prostaglandins. In the rare event that postoperative analgesics must be continued for longer than 5 days, hypertensive patients should return to the office for blood pressure assessment. If pressure has elevated more than 10% above baseline, it would be wise to replace the NSAID with acetaminophen.

Ibuprofen has been found to competitively inhibit the antiplatelet influence of aspirin.^{14,15} It is the only NSAID implicated in this interaction, but diclofenac

and the selective COX-2 inhibitors are the only agents that have been confirmed not to interact.¹⁵ An empiric solution to this problem is predicated on the fact that the antiplatelet influence of low-dose aspirin occurs when it contacts platelets within the hepatic portal system after absorption.¹⁶ Simply advise the patient to take daily aspirin upon arising and to delay the first dose of ibuprofen for 1–2 hours. By this time, the antiplatelet influence of aspirin will have been established.¹⁷ This entire issue may eventually prove moot because its actual clinical relevance has been challenged impressively. Cryer et al¹⁸ found that thromboxane inhibition by aspirin was reduced by only 1% after 10 days of concurrent ibuprofen use, and Patel¹⁹ found no increase in incidence of myocardial infarction over a 10-year period in patients with coronary disease taking ibuprofen with low-dose aspirin.

Recently concern has been introduced regarding increased risk for GI mucosal injury in patients taking selective serotonin reuptake inhibitor (SSRI) antidepressants and NSAIDs. This risk is most significant after prolonged use of NSAIDs, but caution may be advised during short-term use for patients who have a previous history of mucosal injury.^{20,21} Finally, serum levels of lithium and methotrexate are elevated during concurrent consumption of NSAIDs. To prevent toxicity, NSAIDs should be avoided in patients medicated with these agents, particularly those taking high-dose regimens.

Therapeutic Uses. In general, no convincing evidence indicates that a particular NSAID is more effective or safer than other members of this drug class.²² Selective COX-2 inhibitors such as celecoxib produce less GI toxicity after short-term use, but this advantage wanes as consumption continues. Chou et al²³ published an impressive evidence-based analysis of NSAIDs for the Oregon Evidence-Based Practice Center that supports this generalization. Nevertheless, patients vary considerably in their clinical response and GI tolerance to a particular agent. Given its unsurpassed efficacy and low side effect profile and cost, ibuprofen is generally a sound initial choice. Regardless of the agent selected, however, an optimal dosing schedule should be maintained for 2–3 days before an alternative agent is prescribed. It is reasonable to select an alternative NSAID for initial therapy for patients who appear to question the effectiveness of a product that is available over-the-counter. Regardless of the NSAID selected, clinical considerations are identical.

All NSAIDs have greater potency as analgesics and antipyretics than as anti-inflammatory agents; higher doses are required to achieve anti-inflammatory than




Figure 2. Analgesic efficacy. This graph illustrates a typical dose-response curve for orally administered (PO) analgesics. The dose-response curve for opioids such as morphine demonstrates unlimited efficacy in which greater doses provide greater analgesia. At equipotent doses, all opioids demonstrate a similar dose response. In contrast, nonopioids demonstrate a “ceiling” effect that generally is adequate for relief of mild to moderate pain (pain relief rating of 4–5 in this scale). For ibuprofen, doses greater than 400 mg do not provide further analgesia. For aspirin (ASA) and acetaminophen (APAP), this ceiling effect is achieved at 1000 mg and is somewhat lower than that provided by nonsteroidal anti-inflammatory drugs (NSAIDs).

analgesic effects. This may reflect a different site of action for analgesic versus anti-inflammatory actions (eg, CNS vs periphery), but this has not been confirmed. For example, a single 200- to 400-mg dose of ibuprofen may reduce pain and fever, but daily consumption of 1600–2400 mg may be required to suppress inflammation adequately. Nevertheless, if we consider only their analgesic properties, the dose-response curves for nonopioids (NSAIDs and acetaminophen) exhibit a ceiling effect; additional increases in dose provide no further benefit (Figure 2). The ceiling responses for aspirin and acetaminophen occur at 1000 mg, and the analgesic ceiling for ibuprofen is achieved at 400 mg.^{24,25} As the dose of an NSAID is increased, anti-inflammatory effects improve until maximum safe doses preclude any further increase. Most NSAIDs have ranges in their recommended dosages, but precise doses for their analgesic ceilings have not been determined. It is reasonable to presume that the lower doses, like those for ibuprofen, confer analgesia, and the higher range adds anti-inflammatory efficacy. With this in mind, lower dosages should be selected for noninflammatory pain, and higher ranges are reserved for those situations in which inflammation and swelling are significant cofactors. Of course most cases of dental pain have at least some degree of contributing inflammation.

Preoperative use of NSAIDs has been demonstrated repeatedly to decrease the intensity of postoperative pain and swelling.^{26,27} This is not surprising because NSAIDs inhibit the “formation” of prostaglandins; however, they do not destroy or inhibit those already formed. More recent understanding of pain mechanisms reveals that benefits of this practice are evident so long as prostaglandin synthesis is inhibited before local anesthesia wanes. Otherwise, prostaglandins trigger nociceptive impulses that travel to the brain and “wind up” the brain’s interpretation of pain intensity. When an extensive surgical procedure is planned, optimal serum levels of an NSAID should be established preoperatively or before patient discharge, while tissues remain anesthetized. This “preemptive analgesia” may be useful for endodontic and extensive restorative procedures as well.

COX-2 Inhibitors

As was stated previously, clinical trials comparing the COX-2 inhibitors (eg, celecoxib [Celebrex]) versus conventional NSAIDs have not identified substantive differences in their anti-inflammatory or analgesic efficacy.^{22,23} Clinical studies have found celecoxib less effective as an analgesic when compared with ibuprofen and naproxen.²² COX-2 agents offer the advantages of no increase in bleeding time and minimal GI injury despite a comparable incidence of dyspepsia. However, controversy persists regarding their risk for thrombotic events in patients with atherosclerotic disease. As is illustrated in Figure 1, selective COX-2 inhibition tilts prostanoid production toward platelet aggregation. Indeed several publications have suggested an increase in acute coronary events in patients with preexisting CAD who have been medicated with COX-2 inhibitors. In fairness, this correlation has been found with most of the nonselective NSAIDs as well. Naproxen is the only NSAID that appears to lack this correlation. Nevertheless, it is probably wise to avoid selective COX-2 inhibitors in patients with significant atherosclerotic disease.

Acetaminophen

Actions and Effects. Compared with NSAIDs, the mechanism of action of acetaminophen is less clear but is believed to involve an inhibition of prostaglandin synthesis within the CNS.²⁸ It has little influence on peripheral prostaglandin synthesis, especially within inflamed tissues.⁷ This is a likely explanation for its lacking anti-inflammatory efficacy and sharing none of the peripheral side effects attributed to NSAIDs. However, it is an ideal analgesic for patients who present

Table 1. Nonopioid Analgesics*†

Product	Dosage
Ibuprofen (Motrin)	400–800 mg tid/qid
Flurbiprofen (Ansaid)	50–100 mg tid
Ketoprofen (Orudis)	25–75 mg tid/qid
Naproxen sodium (Anaprox)	550 mg bid
Diflunisal (Dolobid)	1000 mg STAT, then 500 mg q8–12h
Diclofenac potassium (Cataflam)	50–100 mg STAT, then 50 mg tid
Celecoxib (Celebrex)	200 mg qd/bid
Acetaminophen (Tylenol)	500–1000 mg tid/qid

* Acetaminophen and those nonsteroidal anti-inflammatory drugs (NSAIDs) most often used as nonopioids for management of postoperative pain and inflammation.

† Adapted from Abramowicz.²²

any contraindications to NSAIDs. As an analgesic and antipyretic, acetaminophen is equal in potency and efficacy to aspirin²⁹ and presumably may be somewhat inferior to ibuprofen and other NSAIDs as well.

Hepatotoxicity is the most significant adverse effect of acetaminophen. It is attributed to a toxic metabolite that cannot be adequately conjugated when dosages exceed 200–250 mg/kg in a 24-hour period.³⁰ The dose may be less for patients who are poorly nourished, who have liver dysfunction, or who are being treated with other hepatotoxic medications. For example, in contrast to the 4 g/d allowed healthy patients, those suspected of chronic alcoholism should limit their maximum daily intake to 2 grams.

Summary of Nonopioids

Most cases of postoperative dental pain include an inflammatory component. For this reason, NSAIDs are the most rational first-line agents—often superior to conventional dosages of opioids. Should a patient present a contraindication to NSAIDs, acetaminophen is the only alternative. Nonopioids exhibit a ceiling to their analgesic response, but optimal doses should be established before it is assumed that the NSAID has failed. Furthermore, the combination of an NSAID with acetaminophen provides greater analgesic efficacy than does either agent alone,³¹ and this strategy may obviate the need for opioids. Data relevant for prescribing the most commonly used nonopioids are summarized in Table 1.

OPIOID ANALGESICS

Actions and Effects

Opioids produce most of their therapeutic and adverse effects by acting as agonists at opioid receptors. Scien-

Table 2. Action of Opioids*†

Receptors	mu (μ)	kappa (κ)
<i>Effects in Common</i>	Analgesia Respiratory depression Sedation	Analgesia Respiratory depression Sedation
<i>Other Effects</i>	Euphoria, dependence Constipation	Dysphoria/ Psychomimetic
Morphine	+++	+
Nalbuphine	--	++
Naloxone	---	--

* The most significant opioid effects are mediated through mu and kappa receptors. Effects generated by mu receptors produce an unlimited dose response, but those mediated by kappa receptors have a ceiling to their effects. Opioids act as agonists or antagonists at these receptors.

† + indicates relative affinity as an agonist; –, relative affinity as an antagonist.

tists have not entirely established the physiological significance of these receptors, but they are activated by a variety of endogenous ligands, collectively called *endorphins*. Opioid receptors germane to clinical practice are located within the CNS, but peripheral receptors have also been characterized.² Unlike nonopioids, which exhibit a ceiling analgesic response, opioids demonstrate greater efficacy as the dose is increased (Figure 2). Unfortunately, when pain is very severe, side effects may preclude the use of doses adequate to produce complete analgesia.

Only 2 of the 5 opioid receptors isolated thus far have relevance for clinical practice. The effects mediated by mu and kappa receptors are summarized in Table 2. Morphine produces its effects by acting as an agonist at both mu and kappa receptors, while naloxone acts as an antagonist.³²

The mu receptor is responsible for mediating analgesia and 2 of the most undesirable side effects attributed to opioids: respiratory depression and dependence. Mu effects have unlimited intensity, increasing proportionately with dose. Therefore, a striking contrast exists between the unlimited analgesic efficacy of mu agonists and the limited or ceiling effect described for the nonopioids.

Like mu receptors, the kappa receptor mediates analgesia and respiratory depression, but efficacy at this receptor is limited.²⁸ These 2 receptors provide comparable efficacy after doses equivalent to 10 mg morphine IM, but the response from kappa receptors does not increase with greater doses. When high doses of opioids are used, selective kappa agonists are viewed as safer, but less analgesic, compared with traditional mu agonists.

Knowledge regarding the kappa receptor spawned the synthesis of several novel compounds that act as

agonists at kappa receptors but act as antagonists at mu receptors. Nalbuphine (Nubain) is an example (Table 2). These so-called agonist-antagonists are not constipating, produce less respiratory depression at higher doses, and have less potential for abuse, but their limited analgesic efficacy diminishes their value when postoperative pain is severe. Higher doses are no more effective than conventional doses. Because they act as antagonists at mu receptors, agonist-antagonists may precipitate a withdrawal syndrome in patients dependent on opioids. They are good choices for patients who have a previous history of drug seeking, but they must never be given to a patient who is currently dependent. Dysphoric reactions produced by these agents were formerly believed to be mediated by sigma receptors. However, this receptor is no longer considered an opioid receptor, and dysphoria is credited as a kappa receptor phenomenon.³²

Dependence, Tolerance, and Addiction

Fear of dependence and addiction often results in underprescribing of opioids for severe acute, chronic, and even terminal pain. This unfortunate practice is due to poor understanding of dependence, tolerance, and addiction.

Dependence occurs when the body accommodates to the influences of a drug and, upon sudden discontinuation, the patient experiences a withdrawal syndrome that generally includes reactions opposite those produced by the particular drug. For example, opioids produce sedation, lethargy, and constipation. A patient who is experiencing opioid withdrawal becomes excited and experiences abdominal cramping and diarrhea. If opioid doses are tapered gradually, a dependent patient will not experience withdrawal. Patients who consume opioids regularly for longer than a week can develop some degree of dependence. This may require gradual tapering of the dosage to avoid withdrawal symptoms, which can be confused as an exacerbation of the painful condition. However, this does not mean that the patient has become addicted.^{22,32}

After repeated administration, patients develop tolerance to opioids. This is to say that greater doses are required to produce the same intensity of effect formerly provided by a smaller dose. Tolerance to analgesia, sedation, and respiratory depression occurs simultaneously, but it is curious that no tolerance occurs to the constipating or miotic effects of opioids. This is problematic for the patient with chronic or terminal pain. Although staggering doses may be required to control pain and generally will not jeopardize the patient's respiratory status, constipation can become ex-

tremely severe, and night vision becomes impaired. Similar doses, if administered to patients who have not developed tolerance (ie, opioid-naive patients), would certainly be lethal. These identical issues must be considered when one is managing dental pain for patients who are chronic opioid abusers.

Addiction is distinct from dependence or tolerance. It is a compulsive behavior centered on seeking a drug and its effects for nonmedical reasons—generally for pleasure. It is a complex psychiatric phenomenon, but it should not be attributed to the drug. Addictive behavior can be reinforced by a particular drug, but it is not a pharmacodynamic property. A patient who lacks addictive behavior can be easily weaned from opioid dosages without fear of precipitating addictive behavior. In contrast, an addicted patient will seek the drug despite having no remaining evidence of dependence or medical need for the drug. Opioids produce dependence, even after as little as 5–7 days of therapy, and this may require institution of a tapering dosage schedule. However, opioids do not produce addiction; they should not be withheld on the presumption that the patient will become “addicted.”³² Obviously, opioids must be prescribed cautiously for patients who demonstrate addictive personality.

Therapeutic Considerations

Despite recent scientific literature to the contrary, many believe that certain opioids are more effective or more dangerous than others. This is simply not the case; equipotent doses are equianalgesic. When administered subcutaneously or intramuscularly, 10 mg morphine, 75 mg meperidine, and 120 mg codeine all produce equivalent analgesia and side effects.³² However, as will be explained below, issues regarding metabolism and activity of metabolites have been noted with some of these agents.

After oral administration, gastric degradation and first-pass metabolism require that larger doses be used if one is to achieve analgesia comparable with that following parenteral administration. For example, the oral-to-parenteral dose ratio for morphine is generally regarded as 3 : 1. If one is to duplicate the analgesic efficacy of a standard 10-mg IM injection of morphine, a 30-mg oral dose must be prescribed. Equianalgesic doses of commonly used opioids are found in Table 3.

Effective pain control is predicated on selecting an optimal dose, rather than selecting a particular agent. However, individual differences in patient response and pharmacokinetic differences (eg, duration, elimination half-life) may favor the use of a particular agent. Morphine 7.5–10 mg IM is a relatively safe and common standard

Table 3. Opioid Analgesics*†‡

Product	Duration, h§	T _{1/2} beta (hr)	Equianalgesic Doses, IM/PO
Hydromorphone	4–5	2–3	1.5/7.5 mg
Morphine	3–7	1.5–2	10/30 mg
Methadone¶	4–6	15–30	10/20 mg
Meperidine	2–4	3–4	75–100/300 mg#
Codeine	4–6	3	120/180–200 mg**
Hydrocodone	4–8	3.3–4.5	ND/30 mg
Oxycodone	4–6	ND	NA/20 mg††
Propoxyphene	4–6	6–12	ND/200 mg‡‡

* Pharmacokinetic data and equipotent doses of commonly used opioids are summarized in this table. Although 10 mg morphine or 75 mg meperidine administered IM is a standard reference dose for moderate to severe postoperative pain, lower equivalent doses can be used if combined with a nonsteroidal anti-inflammatory drug (NSAID) or acetaminophen (APAP).

† NA indicates not available for IM use in the United States; ND, no data available.

‡ Adapted from *Facts and Comparisons 2009*. (Olin BR, Hebel SK, Dombek CE, editors. Drug Facts and Comparisons. 2009 edition. St Louis: Facts and Comparisons, Inc 2009).

§ Based on IV data. After oral use, duration may be longer.

|| Based on short-term use. Long-term use (eg, >2 days) may require reduction because of altered kinetics and reduction in the oral-to-parenteral ratio.

¶ Duration and half-life increase with repeated doses because of drug accumulation. Do not exceed drug manufacturers' recommendations for dosage intervals.

Accumulation of toxic metabolite (normeperidine) precludes long-term use (>2 days).

** Oral doses generally are limited to 90 mg to avoid excessive nausea and constipation from the prodrug.

†† Derived from sources other than texts cited for other data. Most tables in traditional texts list 30 mg oxycodone as equipotent. Empiric data and numerous journal articles suggest that this is excessive, and that 20 mg is more appropriate.

‡‡ 130 mg for HCl salt and 200 mg for Napsylate salt. These doses are the maximum recommended but may not be equipotent with other opioids in this table.

for inpatient analgesia. By using this as a reference point, one can select equianalgesic doses of other agents for both parenteral and oral regimens. The opioid doses listed in Table 3 are equianalgesic and present equivalent risks for serious side effects.

Considerations for Specific Opioids

Codeine has very little affinity for the mu receptor and may be considered a prodrug because 10% of the parent drug is converted to morphine by cytochrome P450 CYP2D6. The morphine metabolite accounts for its entire analgesic effect³² (Figure 3). Altered activity of CYP2D6 offers one explanation for varied responses to codeine and to its derivatives that will be addressed below. Roughly 5–10% of the Caucasian population metabolizes codeine poorly because these individuals have inherited 2 nonfunctional alleles for synthesis of CYP2D6. For them, analgesia resulting from codeine will be less than expected with the general population. It has also been estimated that 1–7% of Caucasians have elevated CYP2D6 activity, and this may account for heightened sensitivity.³³ Likewise, a variety of drugs that a patient may be taking concurrently have the ability to inhibit or induce CYP2D6 activity. For example, the SSRI antidepressants are CYP2D6 inhibitors, making codeine less effective. This is established for fluoxetine (Prozac) and paroxetine (Paxil) but appears less likely with other agents of this class.³⁴ In contrast, dexametha-

son is a CYP2D6 inducer and will enhance the portion of codeine demethylated to morphine.

Hydrocodone and Oxycodone. Hydrocodone and oxycodone are more attractive analgesics than codeine. They also are methylated, but these parent drugs appear to have better affinity for opioid receptors than codeine. Hydrocodone is demethylated to hydromorphone in quantities sufficient to credit both the parent drug and this active metabolite with its analgesic influence. For this reason, hydrocodone shares the same considerations regarding demethylation addressed previously for codeine.³³ In contrast, the analgesic effect of oxycodone is almost entirely attributed to the parent drug because only scant amounts are demethylated to oxymorphone.³³ This makes it the better choice for patients taking medications known to inhibit CYP2D6. Their potency allows for lower doses of these agents and reduces the incidence of nausea compared with codeine.

Unfortunately, equianalgesic doses for these codeine derivatives were poorly understood initially, which spawned release of combination products that contain irrational dosage formulations. Equipotent doses listed in textbooks vary somewhat, but those provided in Table 3 are well accepted and indicate that 200 mg codeine, 30 mg hydrocodone, and 20 mg oxycodone are equipotent oral doses, and these are equianalgesic to the conventional opioid standard of morphine 10 mg IM or




Figure 3. Molecular structures of morphine, codeine, and derivatives. The top row illustrates molecular structures for morphine and its two derivatives, hydromorphone and oxymorphone. The subtle changes indicated by the asterisks enhance affinity for the opioid receptors, which accounts for greater potency. The bottom row illustrates codeine and its derivatives, which differ from their morphine-derived counterparts only in a methyl substitution (circled). Approximately 60% of an oral dose of codeine-related products is absorbed and may be subjected to varying degrees of demethylation by CYP2D6 to its active metabolite. Framed molecules are those credited with the analgesic effect provided by various codeine-related products. Codeine has little affinity for opioid receptors. Roughly 10% of an absorbed dose is demethylated to morphine, which is credited with its analgesic effect. Hydrocodone and oxycodone have good receptor affinity and provide an analgesic effect. The analgesic effect of hydrocodone is credited to both the parent drug and its active metabolite, hydromorphone, but analgesia provided by oxycodone is almost entirely the result of the parent drug. Very little is demethylated to oxymorphone.

30 mg PO. Codeine doses have been well studied, and from this table we find that the oral dose for codeine is approximately 20 times the IM dose of morphine (200 mg vs 10 mg). Clinical studies that have attempted to address equianalgesic doses of codeine derivatives are sparse, but they support this same ratio. Beaver et al³⁵ found that oxycodone 10 mg was comparable with codeine 100 mg, and this would extrapolate to oxycodone 20 mg and codeine 200 mg. Studies by Hopkinson³⁶ and by Beaver³⁷ have shown that hydrocodone 10 mg was approximately equipotent to codeine 60 mg, and this would extrapolate to 33 mg hydrocodone and 200 mg codeine.

It is not uncommon for patients to report previous episodes of nausea as an “allergic reaction.” However, IgE antibodies have been detected that react with several opioids, including codeine,³⁸ and nearly all opioids are capable of triggering degranulation of mast cells leading to the direct release of histamine.³⁹ Until issues regarding cross-reactivity among opioids are resolved, a prudent approach would be to select alternatives that are molecularly dissimilar. For example,

when a patient reports clinical signs that are allergic in nature, one should select an agent that is not derived from morphine or codeine (eg, propoxyphene, pentazocine).⁴⁰

Meperidine. Meperidine 75–100 mg is equianalgesic to morphine 10 mg after IM administration. A significant portion of an IM dose of meperidine is converted to normeperidine, a metabolite that has no analgesic properties but is a noted cardiovascular and CNS stimulant. Furthermore, this metabolite has a 15- to 20-hour elimination half-life, compared with 3 hours for the parent drug.³² For hospitalized patients, meperidine is used for only a day or 2; otherwise, normeperidine will accumulate. In fact, many hospitals have deleted it from their formularies. This issue becomes even more problematic after oral administration in outpatients. Oral bioavailability for meperidine is approximately 25%, which requires a 300-mg dose to be equianalgesic to its IM dose of 75 mg. This introduces an even greater risk for accumulation of normeperidine. Poor oral absorption and accumulation of normeperidine make meperidine a very poor choice as an oral analgesic.

Propoxyphene. Propoxyphene is available only for oral administration. The equianalgesic dose compared with morphine has not been established, but its potency is low. By convention, 100 mg is considered equipotent to oral codeine 60 mg. It is similar to meperidine in that it is converted to norpropoxyphene, a stimulant that has an elimination half-life of 30 hours.³² Its use should be limited to short-term management of mild to moderate pain.

Pentazocine. Pentazocine is the only oral agonist-antagonist analgesic available in the United States. It produces its analgesic effect by acting as an agonist at kappa receptors but is an antagonist at mu receptors. Therefore it reverses all effects of traditional mu agonist opioids if taken concurrently. Unlike mu agonists, which provide unlimited analgesic efficacy, kappa agonists exhibit a ceiling to their analgesic effect, and no benefit is derived by increasing doses beyond 50 mg. Pentazocine is available in the United States for oral use compounded with naloxone to prevent parenteral injection abuse issues. If injected, naloxone will block all effects of pentazocine, rendering it useless. When taken by mouth, however, naloxone has no oral bioavailability and will not hinder pentazocine actions. Additionally, pentazocine is available compounded with APAP. It should not be used in the presence of other opioids. When other opioids are present, pentazocine will serve as an opioid antagonist, thus reducing

the patient's analgesia. Additionally, it should not be prescribed for patients who are opioid dependent and at risk for withdrawal. It is an attractive choice for patients who have a previous history of opioid abuse because it does not provide euphoric effects mediated by conventional mu agonists. Because it is not a mu receptor agonist, constipation is unlikely.

Tramadol. Tramadol is a centrally acting analgesic with binary action. It is not classified as a controlled substance in the United States. The parent drug inhibits the reuptake of norepinephrine and serotonin. This resembles the action of tricyclic antidepressants and potentiates descending neural pathways that inhibit incoming nociceptive impulses. This action has proven efficacy in the management of chronic pain. However, any benefit for tramadol in acute postoperative pain management is not as well defined. The principal metabolite of tramadol, *O*-desmethyltramadol (M1), demonstrates agonist action on mu receptors, providing analgesic efficacy approximating that of codeine 60 mg. Formation of this metabolite is provided by CYP2D6 enzymes and introduces the identical risk for drug interactions described earlier for codeine. Tramadol is not recommended for patients with a tendency toward opioid abuse or dependence.⁴¹ It is available in combination with acetaminophen but is no more effective than codeine-acetaminophen combinations.⁴²

SELECTING ANALGESIC REGIMENS

Mild to moderate pain generally can be managed by using optimal doses of nonopioids: ibuprofen 400–800 mg, acetaminophen 1000 mg, or a combination of the two. Although it is unwise to combine NSAIDs, the addition of acetaminophen to an NSAID is reasonable because they have different sites for their analgesic action.^{31,43,44} Regardless of pain severity, one should seek to optimize “around-the-clock” dosages of these agents and then, if necessary, add an opioid to the regimen as needed for breakthrough pain. This practice generally will reduce the amount of opioid required, sometimes to only a fraction of the maximum doses listed in Table 3. It is irrational to prescribe opioid combinations routinely as “first-line” analgesics.

To further focus on the importance of nonopioid analgesics, refer to the graph provided as Figure 4. These data were derived from a clinical study funded by a drug company to promote a combination product containing ibuprofen and oxycodone.⁵ It is significant that the analgesia provided by single-entity agents reconfirms clinical studies published repeatedly over the past 3 decades. NSAIDs are more effective for muscu-




Figure 4. NSAID versus opioid analgesia. The following data were derived from patients who underwent third molar impaction surgery. See text for explanation. (Ibu 400 = ibuprofen 400 mg; Oxy 5 = oxycodone 5 mg)

loskeletal pain than are conventional doses of opioids. In fact, oxycodone 5 mg (the dose combined with APAP in the most commonly prescribed Percocet tablet) is no more effective than placebo. Notice, however, that a small increment of opioid (oxycodone 5 mg) added to ibuprofen improves pain relief. This illustrates the fact that opioids are synergistic, and analgesia can be improved by titrating additional opioid increments to an optimally dosed nonopioid.

It is not surprising that such a large number of commercially compounded analgesics containing both nonopioid and opioid ingredients have been produced. The opioid contained in most of these products is either hydrocodone or oxycodone. Some of these combinations appear to have been formulated with little consideration given to equianalgesic dosage strategies. Additionally, several products contain large quantities of acetaminophen that preclude the use of multiple tablets to achieve an adequate amount of opioid for patients who experience severe pain. When prescribing combination products, the clinician must pay particular attention to the amount of acetaminophen used separately or compounded so that the maximum daily dose of 4 grams is not exceeded. In many cases, it is better to write separate prescriptions for the opioid and the nonopioid at dosages that more precisely address the analgesic needs of the patient. Suggested regimens are presented in Table 4.

The dentist must be cautious when prescribing for patients managed over the long term with opioids by their physician. Ideally, these patients have contracted with their physician to decline opioid prescriptions from other health care providers.⁴⁵ Regardless of their arrangements, the dentist should avoid increasing the current opioid dose or prescribing additional opioids for postoperative pain control. The patient's daily nonopioid regimen should be optimized, and, if opioids

Table 4. Stepped Approach for Managing Postoperative Pain*†‡

Suggested Regimens	
Step 1	Ibuprofen 400–800 mg tid/qid or equivalent NSAID
	<i>and/or</i>
Step 2	Acetaminophen (APAP) 500–1000 mg qid
	Add any of the following to Step 1 regimen: Oxycodone 5–10 mg or Morphine 15 mg 1 or 2 tabs q4h PRN
	<i>or</i>
	Pentazocine/NX 50 mg or Tramadol 50 mg 1 tab q4h PRN
	<i>or</i>
	Use combinations, provided no APAP included in Step 1
	HC/APAP 5–10/500 1 or 2 tabs q4h PRN
	<i>or</i>
	OC/APAP 5–10/500 1 or 2 tabs q4h PRN
	<i>or</i>
	Pentazocine/APAP 1 or 2 tabs q4h PRN
	<i>or</i>
	Tramadol/APAP 1 or 2 tabs q4h PRN

* Step 1 regimens generally are adequate for mild and most cases of moderate postoperative dental pain. They should be prescribed continuously, “around-the-clock”—not PRN. Effective patient education is absolutely essential if this is to be accomplished. “They must take the medicine even when they are NOT having pain.” When this regimen proves inadequate, or when pain is anticipated to be more severe, Step 2 regimens can be added but should not replace those in Step 1.

† APAP indicates acetaminophen; HC, hydrocodone; and OC, oxycodone.

‡ Adapted from Becker and Phero.⁴⁸

are required, the physician should be asked to temporarily increase the dosage. Pain experienced after dental surgery is additive to the patient’s normal chronic intensity of pain, and opioid tolerance may require a temporary increase in opioid dosage.

SUMMARY

Careful selection of an effective analgesic regimen should be based on the type and amount of pain the patient is expected to experience. This strategy can prevent the stress and anxiety associated with breakthrough pain.^{46–48} When analgesics fail, it is not unusual for patients to make desperate attempts to seek relief. The clinician should develop several safe and effective analgesic regimens based on estimates of anticipated pain intensity. Following are key features for the proper management of acute postoperative pain:

1. Patients benefit from receiving optimal NSAID doses given at regular, “clock-based” time intervals. These agents are effective and relatively safe and re-

duce the need for opioids. In situations where pain can be anticipated, the analgesia may be optimized by commencing administration before local anesthesia wanes (ie, “preemptive analgesia”).

2. Although NSAIDs achieve an analgesic ceiling at their lower dose ranges, it is proper to prescribe higher doses for most cases of dental pain to derive benefit from their anti-inflammatory properties.
3. The site of action of acetaminophen differs from that of NSAIDs. Therefore, the analgesic effect of acetaminophen is considered synergistic when combined with NSAIDs.
4. If the dose of an NSAID, acetaminophen, or their combination has been optimized but pain persists, an opioid should be added. A commercially available combination product containing opioid and acetaminophen may be an option and is easy to prescribe. However, when prescribing these combination products, the practitioner must be cautious not to exceed 4 grams of acetaminophen per day because of concerns about hepatic injury.
5. Because opioids have no ceiling dose, opioid dosing is better accomplished by prescribing it separately in some situations. This allows opioid to be titrated to the analgesic dose required and decreases concern for acetaminophen toxicity.
6. Avoid prescribing any opioid product for patients already receiving opioids for chronic pain disorders and for those under treatment for opioid abuse. It is appropriate to request an increase in dosage from the prescribing physician if necessary.

REFERENCES

1. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. *Science*. 1992;257:1276–1279.
2. Stein CS. The control of pain in peripheral tissue by opioids. *N Engl J Med*. 1995;332:1685–1690.
3. Forbes JA, Kehm CJ, Grodin CD, Beaver WT. Evaluation of ketorolac, ibuprofen, acetaminophen, and an acetaminophen-codeine combination in postoperative oral surgery pain. *Pharmacotherapy*. 1990;10:94S–105S.
4. Fricke JR Jr, Angelocci D, Fox K, McHugh D, Bynum L, Yee JP. Comparison of the efficacy and safety of ketorolac and meperidine in the relief of dental pain. *J Clin Pharmacol*. 1992;32:376–384.
5. Van Dyke T, Litkowski LJ, Kiersch TA, Zarringhalam NM, Zheng H, Newman K. Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of postoperative pain: a double-blind, placebo- and active-controlled parallel-group study. *Clin Ther*. 2004;26:2003–2014.
6. Burke A, Smyth EM, FitzGerald GA. Analgesic-antipyretic agents: pharmacotherapy of gout. In: Brunton LL,

Pain Management Part II: Pharmacologic Management of Chronic Orofacial Pain

Steven Ganzberg, DMD, MS

Professor of Clinical Anesthesiology, College of Dentistry, College of Medicine & Public Health, Dental/Maxillofacial Anesthesiology Residency Program Director, The Ohio State University

The pharmacologic management of chronic orofacial pain involves the use of medications not used routinely in dental practice. Additionally, many drugs are used for long periods of time necessitating careful monitoring for adverse effects and potential drug interactions. This article will review commonly used medications for chronic orofacial pain and highlight important areas of concern.

Key Words: Chronic pain; Orofacial pain; Pain management.

Chronic orofacial pain (COP) comprises a heterogeneous group of disorders that cause ongoing pain in the head and face region. Although there are many proposed taxonomies, one system divides these pains into musculoskeletal, neuropathic, and neurovascular pains. Psychogenic pains comprise yet another category, but true psychogenic pains, such as those associated with conversion disorder or schizophrenia, are so rare that their management will not be addressed in this article.

Musculoskeletal pains consist of temporomandibular joint disorders and masticatory muscular disorders but also include a variety of cervical conditions which refer pain to the head and face, such as cervical myofascial syndromes and cervical facet arthropathies. Neuropathic pains involve those with damage or alteration to peripheral or central pain pathways; the most well known of these is trigeminal neuralgia, but post-traumatic neuropathies are also quite common. Sympathetically mediated pains, such as complex regional pain syndrome, Type 1, are also known to occur in the face. Many nonodontogenic toothaches are, in fact, neuropathic pains—either atypical forms of trigeminal neuralgia or so-called deafferentation pains associated with alteration in pain transduction, transmission, or modulation. Common neurovascular pains include migraine, tension-type headache, cluster headache, and the numerous variants associated with each of these headaches. Because of the wide variety of conditions, many different medication classes are utilized. It

should be noted that there are many sources of chronic orofacial pains—for example, those that arise from ocular, salivary gland, nasal mucosal and intracranial lesions; even from lung cancer. Many of these conditions are not usually treated by the dentist, but the dentist treating orofacial pain must be familiar with the wide range of differential diagnoses for any given presentation.

CHRONIC VERSUS ACUTE PAIN MANAGEMENT

The management of COP differs significantly from that of acute pain. Although all pain has both sensory-discriminative (nociceptive) and motivational-affective (psychological) components affecting overall perception, chronic pain frequently has significant effects on psychological health and, in turn, the patient's ability to cope with daily pain. Depression and anxiety are common and can profoundly affect pain perception; hence, the use of psychotropic medication is common. This article will review pharmacologic management of chronic pain, but the reader should not presume that medication management is the primary treatment modality. For many patients who suffer with chronic pain, psychological therapies are at least as, and sometimes more, important than sound pharmacologic and interventional measures.

Many different medication classes are commonly used as analgesics for chronic pains versus acute pain. These include antidepressants, particularly the tricyclic antidepressants (TCAs)^{1,2} and the selective serotonin-norepinephrine reuptake inhibitors (SNRIs),³⁻⁵

Received June 15, 2010; accepted for publication June 21, 2010.
Address correspondence to Dr Ganzberg at ganzberg.1@osu.edu.

Anesth Prog 57:114–119 2010
© 2010 by the American Dental Society of Anesthesiology

ISSN 0003-3006/10
SSDI 0003-3006(10)

nonsteroidal anti-inflammatory agents (NSAIDs) when an inflammatory component is present, and the opioids. The latter 2 groups were discussed in the previous article, "Pain Management: Part I: Managing Acute and Postoperative Dental Pain."⁶ Only relevant issues associated with the use of these medications in chronic pain versus acute pain will be highlighted in this article.

In addition to these agents, the anti-epileptic drugs (AEDs) are also very commonly used for neuropathic and neurovascular pains.⁷ The muscle relaxants are not as useful in chronic as in acute musculoskeletal pain,⁸ although the antispastics, a different group including baclofen and tizanidine, show utility in a number of disorders. The various primary headaches utilize a wide array of medications from many classes in addition to those above: beta blockers, calcium channel blockers, lithium, "triptans," ergots, and others.

In regard to dosing for COP, medications should be prescribed on a time contingent basis and, if appropriate, medications with longer dosing intervals are preferable. The need for patients to take medications frequently during the day, as well as on an as-needed basis, reinforces pain behaviors in some individuals. Compliance is a much more complicated issue in COP versus acute pain mentioned in the previous companion article.

NONSTEROIDAL ANTI-INFLAMMATORY DRUGS

NSAIDs are most commonly used for musculoskeletal COP, such as temporomandibular joint disorders and myofascial syndromes. Part I of this series discussed NSAID pharmacology. As opposed to acute pain pharmacotherapy, when any medication is used on a long-term basis as for many chronic pain conditions, the risk of adverse effects increases and monitoring becomes more essential. Long-term NSAID use requires laboratory monitoring for GI bleeding, adverse renal effects, and possible hepatic effects. An initial complete blood count and chemistry to include at least blood urea nitrogen and creatinine blood levels are useful, but baseline aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels are helpful because frequently these patients are taking multiple hepatically metabolized agents. Depending on the patient's underlying medical conditions, follow-up laboratory studies at 1–3 months and regularly thereafter should be instituted. The patient can also be questioned as to dyspepsia, dark stool, or worsening of pre-existing asthma. Long-term medication use also increases the risk and consequences of adverse drug in-

teractions. These include loss of hypertension control with any antihypertensive, due in part to NSAID-induced decreased renal blood flow and increased renin release. Renal toxicity is of particular concern in patients taking angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, and beta blockers because the combination of NSAIDs and these agents can cause loss of renal blood flow autoregulation. Patients with congestive heart failure who are using these medications are particularly at risk. Those taking sulfonyleurea oral hypoglycemic agents may have increased free plasma drug concentration, with resultant hypoglycemia, when NSAIDs, which are highly plasma protein bound, are used long term. Of course, warfarin (Coumadin) and traditional NSAIDs should not be prescribed concomitantly. Toxicity with methotrexate, as used for many autoimmune conditions, and lithium salts, as used for bipolar disorder or cluster headache, can occur when NSAIDs are prescribed with these agents. Interestingly, of all the drugs used for COP, NSAIDs are some of the most concerning when used for long periods of time.

OPIOIDS

Opioids have been used for the management of pain for centuries, and the pharmacology of these agents was also discussed in Part I of this series. There is less controversy today over the use of opioids for chronic pain than in the past.^{9,10} Nevertheless, there are reasons that long-term opioids are not appropriate for many patients with chronic pain, but that discussion is beyond the scope of this article. When used, long-acting and/or sustained-release formulations of agents, such as morphine (MS Contin, Oramorph SR, Avinza, Kadian), oxycodone (OxyContin), oxymorphone (Opana), methadone, and levorphanol are preferred. The latter 2 agents have N-methyl-D-aspartate (NMDA) blocking effects as well. Fentanyl transdermal patches are also available. Short-acting agents can be considered for breakthrough pain but only when clear indications exist. It can be challenging, however, for even the most experienced clinician to distinguish between tolerance and exacerbation of the existing pain condition. It must be remembered that the use of combination opioids (eg, hydrocodone or oxycodone with acetaminophen) can easily lead to acetaminophen toxicity in the chronic pain patient. If acetaminophen or NSAIDs are indicated, they can be added as separate agents to opioid-only medications in order to control nonopioid dosage. An important opioid issue in COP is that long-term analgesic use in migraine and tension-type headache leads to a condition termed "analgesic rebound headache," which is refractory to normal therapy until analgesics are discontinued.¹¹

If long-term opioids are used for chronic pain, a pain contract identifying the responsibilities of patients and prescribers is highly recommended and required in some states. Continued prescribing should be tied to increased activity and productivity levels, as well as other documentation of efficacy. The support of a pain psychologist to further evaluate mental health and improvement in function is very desirable. Laboratory testing to identify diversion and use of illicit substances should be considered at regular, unscheduled intervals. Addiction is not thought to be a frequent concern in the chronic pain population but can occur.¹² As the definition of addiction implies continued use despite harm, and the chronic pain patient presumably derives a medical benefit from pain reduction, “addiction” may need to be defined differently for this patient population or another term used. Certainly, dependence and tolerance can and do develop, but many patients can maintain a stable opioid dose for long periods of time. Others require changing to different opioids periodically to maintain benefit. The most common and disturbing adverse effect is constipation, which is managed initially whenever long-term opioids are prescribed. Respiratory depression and orthostatic hypotension are rarely observed with careful titration. Nausea, when it occurs, can usually be managed with a change in opioid without having to rely on adjunctive agents. Opioids are remarkably safe from a physiological standpoint when titrated appropriately. Regardless, the use of long-term opioid therapy should be reserved for dentists with special training or experience. Dentists are strongly encouraged to follow state medical board (physician) requirements for chronic opioid therapy, as this is becoming a highly scrutinized and regulated area of practice. For most dentists, patients requiring long-term opioid therapy should be referred to qualified medical or dental practitioners. For patients who are currently prescribed opioids for chronic pain by another physician, dentists should consult with or at least notify the opioid prescriber regarding additional opioids that may be prescribed for postoperative pain.

ANTIDEPRESSANTS

Antidepressants have been used for chronic pain for some time (despite lack of FDA approval until recently for some agents), and the link between depression and chronic pain is clear. It is known that descending pain modulation pathways release serotonin (5-hydroxytryptamine or 5-HT) and norepinephrine (NE) to suppress pain transmission. The depressed patient has a dysfunctional 5-HT or NE system, which likely implies

a dysfunctional 5-HT or NE pain modulation pathway. This may explain comorbid pain symptoms in patients with depression. Likewise, patients with chronic pain are more prone to depression due to the burden that daily, continuous pain can inflict. It is usually impossible and unnecessary to separate these components. What is clear is that not all antidepressants have analgesic characteristics and that the analgesic effect is independent of the antidepressant effect.^{1,13} Particularly for TCAs, the dose for analgesia is well below therapeutic doses for depression, and the time to analgesic effect is much sooner than for antidepressant activity. It also appears that NE reuptake blockade, not just 5-HT reuptake blockade, is particularly important; hence, TCAs and SNRIs are the most widely used antidepressants for pain control. When TCAs are used, secondary amines (nortriptyline, desipramine) are frequently preferred due to fewer adverse effects such as sedation, dry mouth, and orthostatic hypotension. However, when sleep is poor and nocturnal bruxism is present, a tertiary amine (amitriptyline, imipramine) can be used at bedtime. TCAs are useful for most COP, including musculoskeletal pains, neuropathic pains, migraine, and tension-type headache. The newer SNRIs, venlafaxine (Effexor), duloxetine (Cymbalta), and desvenlafaxine (Pristiq), are used increasingly for chronic pain, and particularly neuropathic pain. Cymbalta and Pristiq are FDA-approved for certain neuropathic conditions. The selective serotonin reuptake inhibitors (SSRIs) such as paroxetine (Paxil) and fluoxetine (Prozac), while as effective as other antidepressants for depression, do not possess analgesic properties.¹⁴ They certainly may be useful for treating depression in the COP patient and hence improve coping and daily function, but actual pain levels may not decrease. The monoamine oxidase inhibitors (MAOIs) are no longer used for pain except possibly for refractory migraine. The other miscellaneous antidepressants are less useful, although trazodone can be used as a non-dependence-producing sleep adjunct, and bupropion has less adverse sexual effects than other antidepressants and has some support for neuropathic pain.¹⁵ An important issue for dentistry is that SSRIs and probably SNRIs can initiate bruxism in some patients. The use of antidepressants for pain is complex, and the limitations of this article do not allow an in-depth review of indications, adverse effects, drug interactions, and other considerations in prescribing these agents.

ANTI-EPILEPTIC DRUGS

The use of AEDs is common in pain practice, particularly for neuropathic pain and the primary headaches. These agents are thought to limit neuronal excitation

and enhance inhibition. Various sites of action include voltage-gated ion channels (ie, sodium and calcium channels), ligand-gated ion channels, the excitatory receptors for glutamate including N-methyl-D-aspartate receptors, and the inhibitory receptors for GABA and glycine. Carbamazepine (Tegretol) was classically the first line agent for typical trigeminal neuralgia (tic douloureux). Phenytoin has also been used but with less success. These drugs, however, have many adverse effects and can induce serious blood dyscrasias requiring careful and regular laboratory monitoring. Divalproex sodium (Depakote) is frequently used for headache and neuropathic pain and is currently FDA-approved for migraine prophylaxis. Lamotrigine (Lamictal) is useful for neuropathic pain but life-threatening rash (epidermal necrolysis) makes this a second or third line agent. The introduction of gabapentin (Neurontin) to the USA in 1994 led to a resurgence in the use of AEDs for pain management. Although developed to mimic GABA, the agent has no effect on GABA receptors but instead inhibits CNS voltage dependent calcium channels and likely those involved in pain transmission. Later evidence suggested a role in increasing GABA synthesis, so the exact mechanism of action is unclear. What is clear is that the medication was useful for a wide range of pain conditions with minimal adverse effects except for sedation and rare fluid retention.^{16,17} The agent is renally excreted unchanged and not significantly plasma protein bound, making it very prescriber friendly. Newer AEDs were subsequently developed and have proven useful for chronic pain. These include tiagabine (Gabitril), topiramate (Topamax), and pregabalin (Lyrica), which all have GABA-ergic and for some, other pharmacodynamic effects such as inhibition of calcium channels. Many of these agents are also used off-label by psychiatrists for anxiety and bipolar disorders. Lyrica is the only drug FDA-approved for fibromyalgia. The mechanism of levetiracetam (Keppra), another newer agent, is not known. Common to these newer agents is the lack of serious adverse effects such as was seen with the older generation AEDs. Yet another recently introduced drug, oxcarbazepine (Trileptal) functions similarly to carbamazepine as a sodium channel blocker but without the significant incidence of serious blood dyscrasias. It does, however, have a relatively high incidence of hyperammonemia and syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH) which can also arise with other AEDs with varying occurrence rates. As with the antidepressants, the limitations of this article do not allow an in-depth review of indications, adverse effects, drug interactions, and other considerations in prescribing these agents.

Muscle Relaxants

- Carisoprodol (Soma)
 - Chlorzoxazone (Parafon Forte)
 - Cyclobenzaprine (Flexeril)
 - Metaxalone (Skelaxin)
 - Methocarbamol (Robaxin)
 - Orphenadrine (Norflex)
-

MUSCLE RELAXANTS/ANTISPASTICS

As mentioned above, the CNS-acting muscle relaxants (see Table) are generally not very useful for chronic muscular conditions and all are quite sedating. Importantly, cyclobenzaprine (Flexeril) is structurally related to the TCA amitriptyline, has similar effects, and can be useful for some pains and nocturnal bruxism. Additionally, carisoprodol (Soma), a derivative of meprobamate, has anxiolytic properties and the potential for dependence. The antispastic agents baclofen (Lioresal) and tizanidine (Zanaflex) are interesting medications, however. Baclofen, a GABA_B agonist, is useful for some muscular complaints but is also effective for trigeminal neuralgia.¹⁸ Tizanidine, an alpha-2 agonist, has good muscle relaxing properties and like all alpha-2 agonists has sedative and analgesic properties as well.

HEADACHE

The treatment of the primary headaches—migraine, tension-type headache, cluster headache, and their variants—is too complex a topic for this review. What can be said is that pharmacologic therapy is divided into symptomatic treatments (opioid and nonopioid analgesics and antiemetics where indicated), abortive treatments for migraine and cluster headaches (“triptans,” ergots, oxygen, steroids), and preventive agents (antidepressants, AEDs, beta blockers, lithium, verapamil). The decision to proceed from symptomatic/abortive therapy to preventive therapy is generally based on the number of disability days per month due to headache. Although this varies among practitioners, approximately 6 disability days or more per month usually leads to consideration of preventive therapy.

CONCLUSION

There are many more medications that can be discussed, including topical agents, but those drugs addressed above are the most commonly used. Important to the anesthesia provider or the dental surgeon is to distinguish why a patient may be using

these medications, as many are used “off-label,” such as the AEDs for psychiatric purposes or for pain management. Patients with chronic pain can be a challenge for the general dentist as well as the dentist with sedation or general anesthesia training. These patients, in general, have dysmodulated pain control systems. They are frequently very somatically focused, so seemingly small, altered sensations can be magnified. We must understand that these perceptions are as real to them as they seem unlikely to us as dentists. Added to this, patients with chronic pain are frequently, and understandably, distressed and also depressed. Those with COP are all the more challenging since the surgical interventions we provide, or for which we provide anesthesia, are in the area of pain reference. With compassionate care, however, these people frequently become our greatest ambassadors.

Pain is a part of the human experience and has benefits as well as liabilities. In chronic pain, the liabilities usually outweigh the benefits. It is hoped that as advances in pain pathophysiology and pharmacology are made, newer agents will be developed to reduce the human suffering that chronic pain inflicts on individuals, families, and society.

REFERENCES

1. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. *Pain*. 1996;68:217–227.
2. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. *J Pain Symptom Manage*. 2000;20:449–458.
3. Wernicke J, Lu Y, D'Souza DN, Waninger A, Tran P. Antidepressants: duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP). In: Abstracts of the 2d Joint Scientific Meeting of the American Pain Society and the Canadian Pain Society. May 2004. *J Pain*. 2004;5(3 suppl 1):S48.
4. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. *Neurology*. 2003;60:1284–1289.
5. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. *Arthritis Rheum*. 2004;50:2974–2984.
6. Becker DE. Pain management: part 1: managing acute and postoperative dental pain. *Anesth Prog*. 2010;57:67–79.
7. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. *BMJ*. 1995;311:1047–1052.
8. van Tulder MW, Koes BW, Bouter LM. Conservative treatment of acute and chronic nonspecific low back pain: a systematic review of randomized controlled trials of the most common interventions. *Spine*. 1997;22:2128–2156.
9. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. *N Engl J Med*. 2003;348:1223–1232.
10. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. *Arch Neurol*. 2003;60:1524–1534.
11. Diener H-C, Limmroth V. Medication-overuse headache: a worldwide problem. *Lancet Neurol*. 2004;3:475–483.
12. Portenoy RK. Opioid therapy for chronic non-malignant pain: a review of the critical issues. *J Pain Symptom Manage*. 1996;11:203–217.
13. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. *Neurology*. 1987;37:589–596.
14. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. *N Engl J Med*. 1992;326:1250–1256.
15. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. *Neurology*. 2001;57:1583–1588.
16. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. *JAMA*. 1998;280:1831–1836.
17. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. *JAMA*. 1998;280:1837–1842.
18. Sist T, Filadora V, Miner M, Lema M. Gabapentin for idiopathic trigeminal neuralgia: report of two cases. *Neurology*. 1997;48(5):146–147.

CONTINUING EDUCATION QUESTIONS

1. Blood dyscrasias are possible side effects of which anti-epileptic drug?
 - A. Carbamazepine (Tegretol)
 - B. Gabapentin (Neurontin)
 - C. Levetiracetam (Keppra)
 - D. Pregabalin (Lyrica)
2. The risk for renal toxicity is enhanced when prolonged use of NSAIDs is combined with which of the following antihypertensive drug classes?
 - A. Diuretics
 - B. Alpha-2 agonists
 - C. ACE inhibitors
 - D. Calcium channel blockers
3. Which of the following side effects is most common when opioids are prescribed continuously for chronic pain?
 - A. Respiratory depression
 - B. Nausea
 - C. Orthostatic hypotension
 - D. Constipation
4. Which CNS neurotransmitter is thought to be most critical in mediating the analgesic effect of antidepressants?
 - A. Dopamine
 - B. Glutamate
 - C. GABA
 - D. Norepinephrine